Central centrifugal cicatricial alopecia (CCCA)

Disproportionately affects women of African ancestry, with reported prevalence of 5–15% in Black women. Typical onset 30s–50s. Rare in men and in non-Black women but does occur. Familial clustering is common; PADI3 loss-of-function variants have been identified in a subset, supporting a genetic substrate. CCCA is not caused by hair styling practices alone — decades of 'hot comb' blaming stigmatized patients; styling may aggravate already-susceptible follicles but is not the primary driver.

Chronic sterile inflammation targets the follicular bulge (stem cell niche). Key histologic feature: premature desquamation of the inner root sheath, leading to disruption of the follicle and concentric lamellar fibroplasia. Over time, follicles are destroyed and replaced by fibrous tracts ('naked hair shafts' in the dermis). PADI3 dysfunction impairs hair shaft formation proteins, predisposing to inflammation. Traction, chemical relaxers, and heat can aggravate but do not alone cause CCCA.

Insidious onset at the vertex/crown, spreading outward concentrically. Earliest finding is loss of follicular ostia with a shiny, atrophic central patch — easy to miss. Hair breakage and decreased density follow. Symptoms include tenderness, pruritus, pins-and-needles, or burning in the affected area, often preceding visible loss.

On trichoscopy: peripilar white/grey halos, pinpoint white dots (scarred follicles), loss of follicular ostia, variable pigmentation changes. Hair shafts may be fragmented or broken at the scalp.

This is fundamentally a disease recognized and defined in skin of color. Key teaching:

• Early = 'central scalp shine' — not overt hair loss. Examine with bright light at close range; look for loss of follicular openings.
• Erythema is often absent — pigmentary changes (hyperpigmented or hypopigmented rim) may be more visible than redness.
• Frequently co-exists with androgenetic alopecia and traction alopecia in the same patient — don't treat as mutually exclusive.
• Biopsy selection matters: take the biopsy from the active (inflamed) peripheral zone, not the burnt-out central scar. Horizontal sections allow follicle counting and identification of premature desquamation.
• Trichoscopy is invaluable and under-used — honeycomb pigment network is normal in textured hair; peripilar casts and loss of ostia are the CCCA markers.
• Patient education must address the myth that her styling caused this — guilt is a major barrier to treatment adherence.

Often overlaps with other hair disorders in the same patient:

• Traction alopecia — marginal (temporal hairline), fringe sign. Can coexist with CCCA.
• Androgenetic alopecia — diffuse central thinning, preserved ostia, no inflammation, no scarring.
• Acne keloidalis nuchae — occipital/posterior neck, keloidal papules around follicles; a separate entity.
• Folliculitis decalvans — tufted hairs, neutrophilic inflammation, boggy pustular lesions; different pathology.
• Dissecting cellulitis — fluctuant boggy nodules, sinus tracts, often young Black men.

• Androgenetic alopecia — preserved follicular ostia, no scarring, no tenderness; biopsy distinguishes.
• Traction alopecia — marginal distribution, fringe sign, history of tight styling.
• Lichen planopilaris (classic) — perifollicular erythema and scale, often at frontal/vertex; biopsy shows lichenoid interface around follicle.
• Frontal fibrosing alopecia — frontotemporal hairline recession, eyebrow loss.
• Discoid lupus erythematosus (scalp) — erythematous scaly plaques with follicular plugging, atrophy; positive DIF.
• Alopecia areata (diffuse) — non-scarring, exclamation point hairs, rapid onset.

• History: onset, rate of progression, symptoms (tenderness, pruritus), styling practices (describe without judgment), family history, medications.
• Exam: full scalp with bright light, document distribution (photos for progression tracking), pull test at periphery.
• Trichoscopy: loss of follicular ostia, peripilar white halos, pinpoint white dots.
• 4 mm punch biopsy from the active peripheral zone (inflamed/symptomatic area), processed for horizontal sections. Two biopsies are ideal: one horizontal, one vertical for DIF/etiology exclusion.
• Labs: only if DLE suspected (ANA, DIF from lesional skin), or to exclude thyroid/iron in mixed presentation.

Classic findings (horizontal section):

• Premature desquamation of the inner root sheath — pathognomonic; inner root sheath absent at the level of the sebaceous gland, where it should still be present.
• Concentric lamellar fibroplasia — whorled fibrosis around follicles.
• Perifollicular lymphocytic inflammation (active disease).
• Reduced total follicular density; loss of sebaceous glands.
• Late disease: naked hair shafts in the dermis (free in stroma after follicle destruction); replacement fibrosis.

Clues for the pathologist: look at isthmus level, horizontal sections, count follicles. Vertical sections alone miss CCCA.

Goal: halt progression. Regrowth of scarred follicles is not possible. Multi-pronged, early, and aggressive.

• Topical high-potency corticosteroids (clobetasol 0.05% solution/foam) nightly to affected area, typically 3-month courses with tapering.
• Intralesional triamcinolone 2.5–5 mg/mL injected into active peripheral zone every 4–8 weeks (usually 3–6 sessions before reassessment).
• Oral doxycycline 100 mg BID for 3–6 months — anti-inflammatory dose, not antibiotic target; alternative: minocycline.
• Topical minoxidil 5% BID — to optimize remaining non-scarred follicles; does not reverse scarring but may improve cosmetic density.
• Hair care counseling — avoid chemical relaxers and high-tension styles during active treatment; gentle detangling, low-heat drying, satin/silk bonnets; frame as protective, not punitive.

• Hydroxychloroquine 200 mg BID — effective in a subset, ophthalmology baseline required.
• Methotrexate 10–25 mg weekly with folate, for severe refractory disease with ongoing inflammation.
• Low-dose oral minoxidil (0.625–2.5 mg daily) — adjunct for density; monitor BP, lower-extremity edema.
• JAK inhibitors (topical ruxolitinib, oral baricitinib) — emerging evidence; consider in ongoing disease despite conventional therapy.
• Hair transplantation — *only* in truly quiescent, stable disease for ≥2 years; recurrence risk in active disease is high.
• Camouflage strategies — scalp micropigmentation, wigs, topical fibers — address QoL while medical therapy works.

Variable. Early-stage CCCA caught during active inflammation and aggressively treated often stabilizes with preservation of remaining follicles. Late-stage disease with extensive scarring is permanent — the affected follicles will not regrow. Progression is often slow (years to decades) but occasionally rapid. Outcomes are better for patients who engage with a dermatologist familiar with textured-hair dermatology.

• Biopsy the active edge, not the burnt-out center. The center shows end-stage scarring only.
• Horizontal sections are mandatory for CCCA diagnosis — vertical alone misses it.
• CCCA and AGA commonly coexist — treat both.
• Do not blame hair styling as the cause — this is medically inaccurate and destroys the therapeutic relationship. Styling may contribute to already-susceptible follicles.
• Itch, tenderness, or burning = active inflammation = therapeutic opportunity. Increase intensity of anti-inflammatory therapy.
• Photography every visit — visual progress is subtle; parting-line photos with a ruler are invaluable.
• Family history matters — ask and counsel affected relatives toward early evaluation.

CCCA is an inflammatory condition with a genetic component. It is not your fault, and hair care did not cause it. Scarred areas will not regrow, but treatment can stop further loss. Treatment is long-term (months to years) and requires consistency. Hair care changes are protective, not punitive — gentle styling, reduced tension, low heat. Wigs and protective styling are valid options during treatment. Psychosocial impact is real; a support group (online communities exist) helps. Encourage affected family members to seek earlier evaluation.